MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Government: International
North America
United States of America
Government: U.S. States & Territories
Government: States (U.S.)
Illinois
Industry: Illinois
Xeris Biopharma Holdings, Inc (NASDAQ: XERS)*
Organization & Developments: Xeris Pharmaceuticals
Parents
Xeris Biopharma Holdings, Inc (NASDAQ: XERS)*
Children
*Developing the G-Pen™, a glucagon rescue pen for emergency treatment of severe hypoglycemia
2018: Xeris Pharmaceuticals Is An Attractive Buy Opportunity In 2018_seekingalpha.com
2019: Our Prognosis On Xeris_seekingalpha.com
2020: Xeris Pharmaceuticals: Marketed Product Company With Platform And Soros Investment Makes Me More Bullish
2021: The Latest On Xeris Pharmaceuticals
2021: Xeris: Recent Success Warrants A Closer Look
2022: Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
2022: Xeris Biopharma: Q3 Earnings Reveals Strong Growth And Path To Breakeve_ seekingalpha.com
2023: Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024_ seekingalpha.com
2024: Xeris Biopharma Updates Its Outlook for 2023
2024: Xeris Biopharma: Checking-In On One Of My 'Top Ideas
2024: Xeris Biopharma: Speculative Buy, Size Your Position Accordingly_(NASDAQ:XERS)_ seekingalpha.com
2024: Xeris Biopharma: Time For A Reassessment
2025: Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator
Jumps
*Key People: Xeris Pharmaceuticals
Finance & Acquisitions: Xeris Pharmaceuticals